vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and MOVADO GROUP INC (MOV). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($346.4M vs $186.1M, roughly 1.9× MOVADO GROUP INC). HAEMONETICS CORP runs the higher net margin — 28.1% vs 5.1%, a 22.9% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (4.8% vs 1.9%). HAEMONETICS CORP produced more free cash flow last quarter ($209.9M vs $11.6M). Over the past eight quarters, MOVADO GROUP INC's revenue compounded faster (2.9% CAGR vs 1.5%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Movado is a luxury American watch brand originally founded in 1881 in Switzerland. Movado means "movement" in Esperanto. The watches are known for their signature metallic dot at 12 o'clock and minimalist style; the company is best known for its Museum Watch.
HAE vs MOV — Head-to-Head
Income Statement — Q4 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $346.4M | $186.1M |
| Net Profit | $97.3M | $9.6M |
| Gross Margin | 57.2% | 54.3% |
| Operating Margin | 36.1% | 6.3% |
| Net Margin | 28.1% | 5.1% |
| Revenue YoY | 4.8% | 1.9% |
| Net Profit YoY | — | 89.8% |
| EPS (diluted) | — | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $346.4M | — | ||
| Q4 25 | $339.0M | $186.1M | ||
| Q3 25 | $327.3M | $161.8M | ||
| Q2 25 | $321.4M | $131.8M | ||
| Q1 25 | $330.6M | $181.5M | ||
| Q4 24 | $348.5M | $180.5M | ||
| Q3 24 | $345.5M | $157.0M | ||
| Q2 24 | $336.2M | $134.4M |
| Q1 26 | $97.3M | — | ||
| Q4 25 | $44.7M | $9.6M | ||
| Q3 25 | $38.7M | $3.0M | ||
| Q2 25 | $34.0M | $1.4M | ||
| Q1 25 | $58.0M | $8.1M | ||
| Q4 24 | $37.5M | $4.8M | ||
| Q3 24 | $33.8M | $3.5M | ||
| Q2 24 | $38.4M | $2.0M |
| Q1 26 | 57.2% | — | ||
| Q4 25 | 59.7% | 54.3% | ||
| Q3 25 | 59.5% | 54.1% | ||
| Q2 25 | 59.8% | 54.1% | ||
| Q1 25 | 58.4% | 54.2% | ||
| Q4 24 | 55.5% | 53.5% | ||
| Q3 24 | 54.2% | 54.3% | ||
| Q2 24 | 52.0% | 54.3% |
| Q1 26 | 36.1% | — | ||
| Q4 25 | 19.9% | 6.3% | ||
| Q3 25 | 17.9% | 2.5% | ||
| Q2 25 | 16.8% | 0.2% | ||
| Q1 25 | 21.6% | 5.1% | ||
| Q4 24 | 16.9% | 3.3% | ||
| Q3 24 | 15.0% | 1.7% | ||
| Q2 24 | 11.8% | 1.6% |
| Q1 26 | 28.1% | — | ||
| Q4 25 | 13.2% | 5.1% | ||
| Q3 25 | 11.8% | 1.8% | ||
| Q2 25 | 10.6% | 1.1% | ||
| Q1 25 | 17.5% | 4.4% | ||
| Q4 24 | 10.8% | 2.7% | ||
| Q3 24 | 9.8% | 2.2% | ||
| Q2 24 | 11.4% | 1.5% |
| Q1 26 | — | — | ||
| Q4 25 | $0.95 | $0.42 | ||
| Q3 25 | $0.81 | $0.13 | ||
| Q2 25 | $0.70 | $0.06 | ||
| Q1 25 | $1.17 | $0.36 | ||
| Q4 24 | $0.74 | $0.21 | ||
| Q3 24 | $0.66 | $0.15 | ||
| Q2 24 | $0.74 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $245.4M | $183.9M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $796.3M | $497.5M |
| Total Assets | $2.4B | $751.9M |
| Debt / EquityLower = less leverage | 1.53× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $245.4M | — | ||
| Q4 25 | $363.4M | $183.9M | ||
| Q3 25 | $296.4M | $180.5M | ||
| Q2 25 | $292.9M | $203.1M | ||
| Q1 25 | $306.8M | $208.5M | ||
| Q4 24 | $320.8M | $181.5M | ||
| Q3 24 | $299.3M | $198.3M | ||
| Q2 24 | $344.4M | $225.4M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $796.3M | — | ||
| Q4 25 | $911.5M | $497.5M | ||
| Q3 25 | $849.2M | $489.9M | ||
| Q2 25 | $882.3M | $493.2M | ||
| Q1 25 | $820.8M | $481.3M | ||
| Q4 24 | $906.9M | $491.3M | ||
| Q3 24 | $878.9M | $492.0M | ||
| Q2 24 | $905.4M | $489.6M |
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.5B | $751.9M | ||
| Q3 25 | $2.4B | $748.7M | ||
| Q2 25 | $2.5B | $747.2M | ||
| Q1 25 | $2.5B | $729.2M | ||
| Q4 24 | $2.5B | $747.2M | ||
| Q3 24 | $2.5B | $742.5M | ||
| Q2 24 | $2.5B | $736.0M |
| Q1 26 | 1.53× | — | ||
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $293.2M | $12.3M |
| Free Cash FlowOCF − Capex | $209.9M | $11.6M |
| FCF MarginFCF / Revenue | 60.6% | 6.2% |
| Capex IntensityCapex / Revenue | 9.5% | 0.4% |
| Cash ConversionOCF / Net Profit | 3.01× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $417.1M | $35.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $293.2M | — | ||
| Q4 25 | $93.6M | $12.3M | ||
| Q3 25 | $111.3M | $-3.8M | ||
| Q2 25 | $17.4M | $-7.2M | ||
| Q1 25 | $116.6M | $39.1M | ||
| Q4 24 | $43.8M | $-4.7M | ||
| Q3 24 | $48.8M | $-17.8M | ||
| Q2 24 | $-27.4M | $-18.1M |
| Q1 26 | $209.9M | — | ||
| Q4 25 | $87.2M | $11.6M | ||
| Q3 25 | $106.3M | $-5.1M | ||
| Q2 25 | $13.6M | $-8.7M | ||
| Q1 25 | $100.9M | $37.5M | ||
| Q4 24 | $35.2M | $-7.2M | ||
| Q3 24 | $39.4M | $-20.1M | ||
| Q2 24 | $-33.1M | $-19.7M |
| Q1 26 | 60.6% | — | ||
| Q4 25 | 25.7% | 6.2% | ||
| Q3 25 | 32.5% | -3.1% | ||
| Q2 25 | 4.2% | -6.6% | ||
| Q1 25 | 30.5% | 20.7% | ||
| Q4 24 | 10.1% | -4.0% | ||
| Q3 24 | 11.4% | -12.8% | ||
| Q2 24 | -9.8% | -14.7% |
| Q1 26 | 9.5% | — | ||
| Q4 25 | 1.9% | 0.4% | ||
| Q3 25 | 1.5% | 0.8% | ||
| Q2 25 | 1.2% | 1.2% | ||
| Q1 25 | 4.7% | 0.9% | ||
| Q4 24 | 2.5% | 1.4% | ||
| Q3 24 | 2.7% | 1.5% | ||
| Q2 24 | 1.7% | 1.2% |
| Q1 26 | 3.01× | — | ||
| Q4 25 | 2.09× | 1.28× | ||
| Q3 25 | 2.88× | -1.27× | ||
| Q2 25 | 0.51× | -5.08× | ||
| Q1 25 | 2.01× | 4.86× | ||
| Q4 24 | 1.17× | -0.98× | ||
| Q3 24 | 1.44× | -5.14× | ||
| Q2 24 | -0.71× | -8.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
MOV
| Other | $81.4M | 44% |
| Owned Brands Category | $46.0M | 25% |
| Sales Channel Directly To Consumer | $35.3M | 19% |
| Company Stores | $23.4M | 13% |
